Deal or Case news
02.06.2023
NautaDutilh assisted Vivoryon Therapeutics a clinical stage company focused on the discovery and development of small molecule medicines in successfully raising EUR 25 million through an accelerated bookbuild offering (ABB).

In the offering Vivoryon issued new shares representing approximately 7.4% of Vivoryon’s existing issued share capital, which will be listed and traded on Euronext Amsterdam.

Vivoryon’s lead product candidate, varoglutamstat is a small molecule medicine in development for the treatment of Alzheimer’s disease.

It was a pleasure to assist Vivoryon in its successful EUR 25 million capital raise
Partner Antonia Netiv

Antonia Netiv, Capital Markets partner, commented: "It was a pleasure to assist Vivoryon in its successful EUR 25 million capital raise. Vivoryon is a truly inspiring company and a great team to work with.”

Related articles

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.